For Appointments

202.741.2210

Active clinical trials for Cancer & Blood Disorders:

TITLE DESCRIPTION
A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients-the INSIGHT-MM study The objective of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in patients with newly diagnosed multiple myeloma and patients with relapsed/refractory multiple myeloma.
More information
A Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for The Treatment of men and Pre/Postmenopausal Women With Hormone Receptor-Positive (HR+) HER-Negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Hormonal Therapy for Advanced Disease The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
More information
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.
More information
A Phase 3, Double-Blind, Placebo-Controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in subjects 18 to 78 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-first) The purpose of this study is to test how well the study medication, quizartinib, works when taken with standard chemotherapy to put AML into remission and then taken alone to prevent relapses of AML.
More information
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy And Safety of Oral Azacitadine Plus Best Supportive Care Versus Best Supportive Care As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission. The purpose of this stud is to determine if oral azacitadine is safe and effective as “maintenance therapy” in continuing the response patients had with their last AML treatment and improving the quality of that response.
More information
A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427) The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC). There will be two cohorts in this study: Cohort A will consist of participants with clear cell (cc) RCC and Cohort B will consist of participants with non-clear cell (ncc) RCC.
More information
A Phase III, Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer Men with newly diagnosed metastatic hormone sensitive prostate cancer and a PSA =2 ng/mL with be randomized to either Androgen deprivation therapy (LHRHa) + TAK-700 (ARM 1) or Androgen deprivation therapy (LHRHa) + Bicalutamide (ARM 2, also the standard of care arm). Patients will be followed for 10 years.
More information
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer. Removing the affected upper urinary tract by surgery is the recommended treatment for upper urinary tract cancer, but can cause loss of kidney function and prevent patients from being able to receive chemotherapy after surgery. Giving chemotherapy before surgery, when the kidneys are working at their maximum, may allow less tissue to be removed during surgery and may be more effective in treating patients with high grade upper urinary tract cancer.
More information
A randomized double blind study to compare the effectiveness and safety of an oral drug plus supportive care vs supportive care as maintenance therapy in patients with acute myeloid leukemia in complete remission To determine the safety and effectiveness of oral azacitidine plus best supportive care vs supportive care only in patient with acue myeloid leukemia in complete remission
More information
A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative early Breast Cancer (PALLAS Study) The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
More information
A Randomized, Phase II Study of CX-01 Combined with Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) The purpose of this study is to find out whether or not the addition of the study drug, CX-01, to standard of care treatment for AML increases the rate of remission.
More information
ARN-509-003: A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with non-Metastatic (M0) Castration-Resistant Prostate Cancer This is a randomized (2:1) trial evaluating the safety and efficacy of ARN-509 versus placebo in men with high risk (M0), non-metastatic castraction resistant prostate cancer (NM-CRPC), defined as PSA doubling time (PSADT) = 10 months
More information
Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2- expressing breast cancer patients to prevent recurrence This is a randomized trial for after all neo or adjuvant therapy is complete for women are Her2 1+ or HER2 2+
More information
Comparing Group Approaches to Improve Insomnia Symptoms Among Breast Cancer Survivors We are inviting women diagnosed with stage I-III breast cancer who have completed active treatment (e.g. surgery, chemotherapy, radiation) to participate in this research study. Through this study we will examine if our mind and body programs improve some of the long term effects of breast cancer treatment such as insomnia. This is a pilot phase of the study. This means that we are interested in feasibility of the program and will ask for your feedback about things you like and do not like about the program.
More information
E1305: A Phase 3, Randomized Trial of Chemotherapy with or without Bevacizumab with Recurrent or Metastatic Head and Neck Cancer The purpose of the study is to find out whether adding a new drug (Bevacizumab) to the standart platinum-based chemotherapy will help improve the survival of patients whose head and neck cancer has either returned after chemotherapy or spread throughout the body.
More information
E2112-A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating postmenopausal patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether exemestane is more effective with or without entinostat in treating breast cancer.
More information
Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer. The objective of this study is to assess the efficacy of induction chemotherapy followed by transoral surgical treatment and neck dissection, in definitive management of moderately advanced oropharyngeal squamous cell carcinoma. The surgical treatment will carry out Transoral Robotic Surgery (TORS) or Transoral Laser Microsurgery (TLM) for the primary tumor, and neck dissection for the management of cervical lymph nodes.
More information
PAC326: A Randomized, Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythermia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis This study will find out if an experimental drug called pacritinib works better than best available therapies.
More information
Randomized Phase 2 study to evaluate 2 dose levels of Imetelstat in patients with myelofibrosis To determine the activity of 2 Dose levels of Imetelstat in subjects with Intermediate-2 or high risk myelofibrosis relapsed/refractory to Janus Kinase inhibitor
More information
Randomized Phase 2 study to evaluate 2 dose levels of Imetelstat in patients with myelofibrosis To determine the activity of 2 Dose levels of Imetelstat in subjects with Intermediate-2 or high risk myelofibrosis relapsed/refractory to Janus Kinase inhibitor
More information
S0931:A Phase III Trial of Everolimus for Renal Cell Ensuing Surgical Therapy This study is for renal cancer patients who have undergone full surgical resection (radical nephrectomy or partial nephrectomy). Patients must be considered pathologically either intermediate hight risk or very high risk for recurrence.
More information
Study of Pembrolizumab With or Without Platinumb-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (KEYNOTE-361) The purpose of this study is to determine the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer).
More information